Joseph L. Fink III, JD, BSPharm, DSc (Hon), FAPhA

These directives are typically used to shape federal agencies and manage employees in the executive branch.

Penalty is incarceration for multiple years and a massive fine.

This movement has aimed to address the mental health care epidemic in the United States.

Appellate court addresses application of legal doctrine to the matter.

Lawsuits were initiated against the pharmacy and prescriber.

Ruling potentially affects federal ability to regulate pharmacy.

Plaintiff argues that "blacklisting” certain individuals with opioid prescriptions was unlawful.

Federal legislation would seek to foster development of antibiotics.

Legislative efforts regarding cybersecurity are ongoing, but individuals and organizations should remain vigilant.

At least 1 patient had a fraudulent tax return filed using illegally obtained personal information.

The money could be used for prevention and treatment services, health care practitioner training, or other ways to stem the epidemic.

In addition to moral arguments, economic issues must be considered.

The question arose whether the court would allow the pharmacist to recover his attorney fees

Multiple requests for delays had been submitted.

Law aims to encourage competition in the pharmaceutical industry, making it easier for generics to enter market.

Expanding capacity of health care outcomes statutes aims to link specialists with general practices.

Eighteen states have enacted legislation that allows pharmacists to help patients when providers are not reachable.

But state-to-state communications and inconsistencies related to licensing present legal issues.

Expectations for pharmacists related to drug utilization reviews lead to examination of woman's death.

But in real-world situations, such as when a bystander administers naloxone, there are gray areas.

Court challenge raises questions about due process and whether agency perceived immediate and serious threat.

Physician expert witness excluded from testifying about standard of care in resulting lawsuit.

Manufacturers file challenge in court resulting in compromise between state government and pharmaceutical companies.